Alivexis, Inc.
PrivateLast Round
Series D
Mar 3, 2025
Total Funding Raised
$59.1M
Company Overview
Alivexis, Inc. operates in Healthcare & Life Sciences and is based in Tokyo. Its latest recorded funding round was a Series D round in March 2025.
Alivexis, Inc. is a biotechnology company that merges cutting-edge drug discovery platforms with disease biology expertise to develop a portfolio of small molecule drugs.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alivexis, Inc. Comparables
Compare Alivexis, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genesis Molecular AI | 86% | |
| Aqemia | 83% | |
| Qubit Pharmaceuticals | 80% |
For institutional investors. Book with your work email.
Alivexis, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Mar 3, 2025 | ||||
| Series C | Mar 1, 2022 | ||||
| Series B | May 13, 2020 | ||||
| Series A | Aug 9, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Alivexis, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| JAFCO Group Co., Ltd. | Series C, Series B |
| Keio Innovation Initiative | Series C, Series B |
| Mizuho Capital | Series B |
| JIC Venture Growth Investments | Series D |
| Heights Capital Management | Series C |
| Mobile Internet Capital | Series B |
| Fast Track Initiative | Series D, Series C, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 19, 2026
Monthly visitors increased 190% MoM, reaching 4.6K.
- Mar 11, 2025
Will present at the GTC 2025 japan AI day event.
For institutional investors. Book with your work email.
Alivexis, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Alivexis, Inc.'s valuation, stock price, and market status.
Is Alivexis, Inc. a public or private company?
Alivexis, Inc. is a private company.
What is the current stock price of Alivexis, Inc.?
Alivexis, Inc. is a private company, so its shares have no public market price. Caplight tracks Alivexis, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alivexis, Inc. worth (valuation)?
Valuation information for Alivexis, Inc. is not publicly available.
Can I buy Alivexis, Inc. stock?
Alivexis, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alivexis, Inc.'s last funding round?
Alivexis, Inc.'s most recent funding round was Series D on March 3, 2025.
Who are the main investors in Alivexis, Inc.?
Key investors in Alivexis, Inc. include JIC Venture Growth Investments, Fast Track Initiative, SBI Holdings.
Will Alivexis, Inc. IPO soon?
No public IPO plans have been announced for Alivexis, Inc..
How can I track Alivexis, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Alivexis, Inc.'s shares on secondary markets.